US 11,987,598 B2
E-selectin antagonist compounds, compositions, and methods of use
John L. Magnani, Gaithersburg, MD (US); Arun K. Sarkar, North Potomac, MD (US); Myung-Gi Baek, Boyds, MD (US); Frank E. Anderson, III, Gaithersburg, MD (US); and Yanhong Li, Rockville, MD (US)
Assigned to GLYCOMIMETICS, INC., Rockville, MD (US)
Filed by GLYCOMIMETICS, INC., Rockville, MD (US)
Filed on Apr. 20, 2022, as Appl. No. 17/724,585.
Application 17/724,585 is a continuation of application No. 16/995,237, filed on Aug. 17, 2020, granted, now 11,332,491.
Application 16/995,237 is a continuation of application No. 16/689,339, filed on Nov. 20, 2019, granted, now 10,766,916, issued on Sep. 8, 2020.
Application 16/689,339 is a continuation of application No. 15/709,141, filed on Sep. 19, 2017, granted, now 10,526,361, issued on Jan. 7, 2020.
Application 15/709,141 is a continuation of application No. 14/752,056, filed on Jun. 26, 2015, granted, now 9,796,745, issued on Oct. 24, 2017.
Application 14/752,056 is a continuation of application No. 14/367,561, granted, now 9,109,002, issued on Aug. 18, 2015, previously published as PCT/US2012/071519, filed on Dec. 21, 2012.
Claims priority of provisional application 61/734,924, filed on Dec. 7, 2012.
Claims priority of provisional application 61/704,424, filed on Sep. 21, 2012.
Claims priority of provisional application 61/704,399, filed on Sep. 21, 2012.
Claims priority of provisional application 61/583,547, filed on Jan. 5, 2012.
Claims priority of provisional application 61/579,646, filed on Dec. 22, 2011.
Prior Publication US 2023/0097694 A1, Mar. 30, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/7034 (2006.01); A61K 45/06 (2006.01); C07H 15/207 (2006.01); C07H 15/26 (2006.01); C09C 1/62 (2006.01)
CPC C07H 15/207 (2013.01) [A61K 31/7034 (2013.01); A61K 45/06 (2013.01); C07H 15/26 (2013.01); C09C 1/62 (2013.01)] 65 Claims
 
1. A method for treating a cancer in a subject comprising administering to the subject a compound of Formula (I) or a pharmaceutically acceptable salt thereof;
wherein the administration is an adjunct therapy to the subject being treated with at least one of chemotherapy and radiotherapy;
wherein the cancer is chosen from at least one of leukemia, lymphoma, and myeloma; and
wherein the compound of Formula (I) is:

OG Complex Work Unit Chemistry